Ovarian Cancer Diagnostics Market Growth, Market Insights and Forecast to 2025Posted by rekha on November 26th, 2019
“The Global Ovarian Cancer Diagnostics Market was valued around US$ 1.4 Bn by 2018 and growing at a significant CAGR of 7.1% over next seven years 2019-2025 due to increase in number of initiatives by governments for ovarian cancer research” The global ovarian cancer diagnostics market accounted for US$ 1.4 Bn in 2018 and burgeoning over the forthcoming years. Some pf the key factors favoring the market growth include increase in number of initiatives by governments for ovarian cancer research, rising prevalence of ovarian cancer, use of combination therapies for the treatment of ovarian cancer, growing geriatric population and rising healthcare expenditure. However, lack of awareness in emerging and low income economies and lack of accurate diagnosis are hampering the market growth. Further, technological advancements would provide huge growth opportunity for the market. Global ovarian cancer diagnostics market segmented on the basis of diagnostic type, disease type, end user and region. Request for Sample Report @ https://www.precisionbusinessinsights.com/request-sample?product_id=17082 Germ Cell Tumour dominate the Global Ovarian Cancer Diagnostics Market Based on disease type, global ovarian cancer diagnostics market is segmented into stromal tumour, germ cell tumour, epithelial tumour and primary peritoneal carcinoma. Germ cell tumour held considerable market growth during estimated period. Germ cell tumours develop in germ cells. These are the cells in the body that develop into sperm and eggs. They are most often developed in the ovary or testicle because this is where most germ cells are.Germ cell tumors in the testes of an adolescent male commonly present as an enlarging, solid mass, which may be painful. Within the ovaries, germ cell tumors can usually be distinguished from ovarian cysts, which are much more common, using ultrasound. Germ cell tumors can spread to lymph nodes, lung, liver, and brain. Some germ cell tumors secrete hormones that can lead to changes resembling puberty. North America Leads the Global Ovarian Cancer Diagnostics market
PBI’s global ovarian cancer diagnostics market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis.North America accounted for larger revenue share in global ovarian cancer diagnostics market with considerable CAGR. The growth in this region is due to increase in healthcare expenditure, favorable government initiatives and existence of key manufacturers. U.S is the major contributor for the market growth in the region. In addition, Asia Pacific held substantial market growth owing to improvement in healthcare infrastructure,rise in consumer awareness and increase in disposable income. India, China and South Korea are witnessing rapid growth due to increasing ovarian cancers. Strategic Approvals are the key strategies adopted by market players
Global ovarian cancer diagnostics market further reveals that the key players increasingly accepting strategies such as approvals of the new products, launch of newer products, recurrent product approvals, and long term alliance to improve market revenue share and gaining significant geographic presence across the regions. For Instance, in June 2019, Foundation Medicine received FDA approved for its FoundationOne CDx, a comprehensive genomic profiling test, for use as a companion diagnostic for LYNPARZA (Olaparib) in first-line maintenance therapy for BRCA-mutated metastatic ovarian cancer. Key player’s profiles in the report are AstraZeneca Plc. (U.K.), Illumina, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Siemens AG (Germany), Roche Holding AG (Switzerland), Myriad Genetics, Inc. (U.S.), Epigenomics AG (Germany), Thermo Fischer Scientific Inc. (U.S.), VolitionRx Ltd. (Singapore), and Abcodia Ltd. (U.K.) Precision Business Insights (PBI) in its report titled “Global Ovarian Cancer Diagnostics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period. Moreover, the report also includes the total revenue and volume for the market.
Detailed Segmentation
By Diagnostic Type o Biopsy o MRI scan o CT scan o PET scan o Ultrasound o Blood test o Others By Disease Type o Stromal tumour o Germ cell tumour o Epithelial tumour o Primary peritoneal carcinoma By End User o Hospitals o Clinics o Diagnostic Centres o Others
By Geography o North America
o Europe
o Asia-Pacific
o Latin America
o Middle East and Africa (MEA)
For more information: https://www.precisionbusinessinsights.com/market-reports/global-ovarian-cancer-diagnostics-market/ Like it? Share it! More by this author |